Clinical Trial: Topiramate Augmentation in Bulimia Nervosa Partial Responders

Study Status: Withdrawn
Recruit Status: Withdrawn
Study Type: Interventional

Official Title: Topiramate Augmentation in Bulimia Nervosa Partial Responders

Brief Summary: The goal of this study is to generate pilot data exploring the addition of an augmentation (additional) medication to patients suffering from bulimia nervosa who have responded but not had complete symptom resolution with a course of standard medication treatment.

Detailed Summary: The aim of this study is to determine whether the addition of an augmentation medication (topiramate 200mg/d) will confer additional reductions in symptomatology in BN patients who have received six weeks of standard pharmacological treatment with fluoxetine 60 mg/day or its equivalent and had a partial response but are not in symptomatic remission.
Sponsor: Neuropsychiatric Research Institute, Fargo, North Dakota

Current Primary Outcome: Weekly number of binge eating episodes and purging episodes [ Time Frame: Weekly for 10 weeks ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Abstinence from BN symptoms [ Time Frame: Baseline and endpoint (week 1 and week 10) ]

Original Secondary Outcome: Same as current

Information By: Neuropsychiatric Research Institute, Fargo, North Dakota

Dates:
Date Received: October 1, 2009
Date Started: September 2009
Date Completion: September 2010
Last Updated: July 13, 2015
Last Verified: July 2015